LETTER TO THE EDITOR

Outcomes of HFNC Use in COVID-19 Patients in Non-ICU Settings: A Single-center Experience

Anivita Aggarwal1, Umang Arora2, Ankit Mittal3, Arunima Aggarwal4, Komal Singh5, Animesh Ray6, Pankaj Jorwal7, Manish Soneja8, Neeraj Nischal9, Akhil K Singh10, Puneet Khanna11, Naveet Wig12, Anjan Trikha13

Keywords: COVID-19 ARDS, High-flow Nasal Cannula (HFNC) oxygen therapy, Outside-ICU.

Indian Journal of Critical Care Medicine (2022): 10.5005/jp-journals-10071-24186

Sir,

Given the spate of coronavirus disease-2019 (COVID-19) cases faced by nations such as India, the total number of critically ill cases, especially during the peaks, has at times overwhelmed its healthcare infrastructure, leading to significant mortality and morbidity. Maintaining oxygenation and adequate respiratory support with the help of non-invasive devices like nasal cannula, face mask, non-rebreathing mask, high-flow nasal cannula (HFNC), and non-invasive ventilation (NIV) have been the pillars of management of this deadly disease. The rapid surge of cases and insufficient numbers of intensive care unit (ICU) beds have forced hospitals to utilize their general wards for the administration of non-invasive respiratory support including HFNC in severe COVID-19. However, there is a dearth of data on the success of such advanced levels of care outside the ICU setting. Therefore, we conducted an observational study at our center to assess the success of HFNC in managing severe COVID-19 cases outside the ICU (Fig. 1).

A retrospective cohort study was performed at our tertiary referral center located in North India between September and December 2020. Patients with severe COVID-19 pneumonia admitted to the ward were initiated on respiratory support via HFNC, if after a trial of high-flow oxygen, they failed to achieve SpO2 ≥90% or a respiratory rate of ≤30 breaths per min. Clinical, laboratory, and treatment information was retrieved from medical records. Outcome parameters included duration of oxygen or HFNC therapy, hospital length of stay, and HFNC failure (ICU transfer or mortality).

During this period, 31 patients received HFNC in the ward, with a median age of 62 (interquartile range [IQR], 50–69) years, including 24 (77%) males (Table 1). HFNC failure occurred in 10 (32%) patients, while 21 (68%) were discharged successfully. They required HFNC for a median of 9 (IQR, 5–12) days, and oxygen therapy was required for a median of 14 (IQR, 11–22) days during admission. Patients with HFNC failure had higher median D-dimer values at baseline (2.2 vs 0.6 mg/L, p = 0.001) and lower initial room-air SpO2 (70 vs 80%, p = 0.026) compared to those in whom HFNC was successful. D-dimer levels predicted HFNC failure well (area under the receiver operating characteristic [AUROC] 0.86), and a cutoff of 1.7 mg/L was found to be optimal.

In hospitals with high influx of COVID-19 admissions and overburdened critical care units, HFNC use in wards could be a life-saving modality for the patients suffering from severe respiratory compromise awaiting ICU care. Our retrospective cohort demonstrated successful outcomes with the use of HFNC in an outside of ICU setting among two-thirds of patients with severe COVID-19 pneumonia. Cohorts studying patients in ICU1 from Japan have found higher levels of D-dimer in those with HFNC failure compared with HFNC success (4.8 vs 2.6 mg/L, p = 0.02). Similar results were reported from few studies done in ward settings, such as Calligaro et al. (1.03 vs 0.56 mg/L, p = 0.002). Similarly, we found a D-dimer level of ≥1.7 mg/L to correctly predict 87% of HFNC failure cases. D-dimer in the appropriate clinical setting may thus help triaging patients at high likelihood of HFNC failure to early ICU transfer and a lower threshold for endotracheal intubation. Predictably, patients with severe COVID-19 pneumonia who have lower oxygen saturation, denoting more extensive pulmonary parenchymal or pulmonary vasculature involvement, are at higher risk of mortality. Consistent with this, in our study, we found median SpO2 at presentation in the emergency department to be higher in those with HFNC success than in those with failure (80 vs 70%, p = 0.036).

HFNC use in out-ICU-setting was found to be successful in managing more than two-thirds of severe COVID-19 patients failing standard oxygen therapy in our cohort. Future studies are required to further confirm the findings of our study as well to explore other relevant aspects of out-of-ICU HFNC use.

1-3,5-8,12Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
4University College of Medical Sciences, New Delhi, India
10,11,13Department of Anaesthesiology, Pain Medicine and Critical Care, All India Institute of Medical Sciences, New Delhi, India
Corresponding Author: Animesh Ray, Department of Medicine, All India Institute of Medical Sciences, New Delhi, India, Phone: +91 033 24079583, e-mail: doctoranimeshray@gmail.com
How to cite this article: Aggarwal A, Arora U, Mittal A, Aggarwal A, Singh K, Ray A, et al. Outcomes of HFNC Use in COVID-19 Patients in Non-ICU Settings: A Single-center Experience. Indian J Crit Care Med 2022;26(4):528–530.
Source of support: Nil
Conflict of interest: None

© The Author(s). 2022 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
**Fig. 1:** Patient outcomes and events during hospital stay

**Table 1:** Patient details, management, and outcomes

| Patient characteristics                  | Total       | HFNC success n = 21 (%) | HFNC failure n = 10 (%) | p value |
|------------------------------------------|-------------|-------------------------|-------------------------|---------|
| Age (years), median (IQR)                | 62 (50–69)  | 60 (50–68)              | 64.5 (53–72)            | 0.41    |
| Male, n (%)                              | 24 (77.4)   | 16 (76)                 | 8 (80)                  | 0.81    |
| Comorbidities, n (%)                     |             |                         |                         |         |
| No comorbidities                         | 10 (32%)    | 9 (42%)                 | 1 (10%)                 | 0.1     |
| Hypertension                             | 15 (48.4)   | 9 (42.3)                | 6 (60)                  |         |
| Diabetes                                 | 16 (51.6)   | 10 (47.6)               | 6 (60)                  |         |
| Coronary artery disease                  | 6 (19.3)    | 3 (14.3)                | 3 (30)                  |         |
| Chronic lung disease                     | 2 (6.6)     | 1 (4.7)                 | 1 (10)                  |         |
| Malignancy                               | 5 (16.1)    | 3 (14.3)                | 2 (20)                  |         |
| Post-transplant                          | 1 (3)       | 1 (4.7)                 | 0 (0)                   |         |
| Chronic kidney disease                   | 1 (3)       | 1 (4.7)                 | 2 (20)                  |         |
| Initial SpO₂ (%), median (IQR)           | 75 (67–84)  | 80 (70–84)              | 70 (65–74)              | 0.036   |
| SpO₂/FiO₂ ratio (%)                      | 192 (172–217)| 196 (188–217)            | 182 (170–211)           | 0.25    |
| Chest radiograph severity score, median (IQR) | 9 (5–12) | 11 (8–15)               | 10.5 (8–16)             | 0.78    |
| Initial inflammatory markers             |             |                         |                         |         |
| CRP (mg/dL), median (IQR)                | 10.37 (1.76–13.85)| 10.81 (2.56–13.85)     | 8.96 (0.74–12)          | 0.52    |
| Ferritin (ng/mL), median (IQR)           | 552.8 (338.1–1056.4) | 605.4 (339.6–1061.3) | 502.95 (219.4–844.3)   | 0.29    |
| IL-6 (IU/mL), median (IQR)               | 30.3 (14.23–87.59) | 33.69 (14.41–103.6) | 22.31 (14.18–49.96)    | 0.31    |
| D-dimer (mg/L), median (IQR)             | 0.8 (0.41–2.13) | 0.6 (0.4–0.9)           | 2.175 (1.7–3)          | 0.0014  |
| Remdesivir use, n (%)                    | 16 (51.6%)  | 12 (57.1%)              | 4 (40%)                 | 0.44    |
| Methylprednisolone dose per day (mg), median (IQR) | 80 (80–120) | 81 (80–80)              | 82 (80–120)             | 0.38    |
| HFNC duration, median days (IQR)          | 9 (5–12)    | 8 (5–11)                | 10 (6–17)               | 0.25    |
| Required mechanical ventilation, n (%)    | —           | —                       | 9 (90%)                 |         |
| Duration of mechanical ventilation, n (%) | —           | —                       | 5 (3–9)                 |         |

(Contd...)
Ours is the first study from India, describing the outcomes of HFNC use in a non-ICU setting among COVID-19 patients. HFNC use outside ICU settings was found to be feasible, with a failure rate of approximately 32% in patients with severe COVID-19 pneumonia. HFNC failure was predicted most reliably by D-dimer at presentation, with a cutoff of 1.7 mg/L having a positive predictive value of 80%.

Orcid
Anivita Aggarwal https://orcid.org/0000-0002-9178-2161
Umang Arora https://orcid.org/0000-0002-4366-0776
Ankit Mittal https://orcid.org/0000-0002-7666-6234
Arushima Aggarwal https://orcid.org/0000-0003-0175-7200
Komal Singh https://orcid.org/0000-0001-6231-3588
Animesh Ray https://orcid.org/0000-0002-9434-5338
Pankaj Jorwal https://orcid.org/0000-0002-3722-4310
Manish Soneja https://orcid.org/0000-0002-8619-7929
Neeraj Nischal https://orcid.org/0000-0002-4751-2914
Akhil K Singh https://orcid.org/0000-0002-6662-9819
Puneet Khanna https://orcid.org/0000-0002-9243-9963
Naveet Wig https://orcid.org/0000-0002-6603-601X
Anjan Trikha https://orcid.org/0000-0002-6001-8486

References
1. Ray A, Jain D, Goel A, Agarwal S, Swaroop S, Das P, et al. Clinico-pathological features in fatal COVID-19 infection: a preliminary experience of a tertiary care center in North India using postmortem minimally invasive tissue sampling. Expert Rev Respir Med 2021;15(10):1367–1375. DOI: 10.1080/17476348.2021.1951708.
2. Raoof S, Nava S, Carpati C, Hill NS. High-flow, noninvasive ventilation and awake (nonintubation) proning in patients with coronavirus disease 2019 with respiratory failure. Chest 2020;158(5):1992–2002. DOI: 10.1016/j.chest.2020.07.013.
3. Kodama T, Obinata H, Morii H, Murakami W, Suyama Y, Sasaki H, et al. Prediction of an increase in oxygen requirement of SARS-CoV-2 pneumonia using three different scoring systems. J Infect Chemother 2021;27(2):336–341. DOI: 10.1016/j.jiac.2020.12.009.
4. Calligaro GL, Lalla U, Audley G, Gina P, Miller MG, Mendelson M, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: a multi-centre prospective observational study. EClinicalMedicine 2020;28. Available from: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30314-X/abstract.
5. Lu X, Jiang L, Chen T, Wang Y, Zhang B, Hong Y, et al. Continuously available ratio of SpO2/FiO2 serves as a noninvasive prognostic marker for intensive care patients with COVID-19. Respir Res 2020;21(1):194. DOI: 10.1186/s12931-020-01455-4.